No Prescription |
 |
 | ||
|
Galamer Razadyne |
|
| ||
No Prescription » Prescription Drugs 8 » Galamer Razadyne Galantamine is indicated in the treatment of Mild-to-moderate Alzheimer's disease.Galantamine can delay or even reverse mental decline in some patients with mild to moderate Alzheimer's disease. It is thought to work by boosting levels of the chemical messenger acetylcholine in the brain. (In Alzheimer's disease the cells that produce acetylcholine slowly deteriorate.) Galantamine improves the function of nerve cells in the brain. It works by preventing the breakdown of a chemical called acetylcholine (ah see til KO leen). People with dementia usually have lower levels of this chemical which is important for the processes of memory thinking and reasoning.Galantamine is used to treat mild to moderate dementia caused by Alzheimer's disease. Buy Galamer Razadyne and other Prescription Drugs 8 products online at Medstore. Buy Online at Medstore - Click Here!
About Galamer Razadyne: Product Type: Prescription Drugs 8 Galamer (Razadyne Reminyl Generic Galantamine) Galamer (Razadyne Reminyl Generic Galantamine) Razadyne Reminyl Generic Galantamine 4mg 50 Tablets 4mg 100(2 x 50) Tablets 4mg 200(4 x 50) Tablets 8mg 50 Tablets 8mg 100(2 x 50) Tablets 8mg 200(4 x 50) Tablets Razadyne Reminyl Generic Galantamine Galamer
View more Prescription Drugs 8 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
